New Health Technologies: A UK Perspective; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies”
Articles in Press, Accepted Manuscript , Available Online from 09 May 2017
The Conceptualization of Value in the Value Proposition of New Health Technologies; Comment on “Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies”
Articles in Press, Accepted Manuscript , Available Online from 03 July 2017
Health Technology Assessment: Global Advocacy and Local Realities; Comment on “Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness”
Volume 6, Issue 4, April 2017, Page 233-236
Kalipso Chalkidou; Ryan Li; Anthony J. Culyer; Amanda Glassman; Karen J. Hofman; Yot Teerawattananon
Comparison of Blood Transfusion Plus Chelation Therapy and Bone Marrow Transplantation in Patients with β-Thalassemia: Application of SF-36, EQ-5D, and Visual Analogue Scale Measures
Volume 4, Issue 11, November 2015, Page 733-740
Mehdi Javanbakht; Ali Keshtkaran; Hossien Shabaninejad; Hassan Karami; Maryam Zakerinia; Sajad Delavari
Incorporating Cost-Effectiveness Data in a Fair Process for Priority Setting Efforts; Comment on “Use of Cost-Effectiveness Data in Priority Setting Decisions: Experiences from the National Guidelines for Heart Diseases in Sweden”
The Use (or rather the non-Use) of Cost-Effectiveness Data in Priority Setting Decisions – Are We Underestimating the Barriers to Using Health Economics in Real World Priority Setting Decisions?; Comment on “Use of Cost-Effectiveness Data in Priority Setting Decisions: Experiences from the National Guidelines for Heart Diseases in Sweden”
Top